Chemomab Therapeutics (CMMB) Short Interest Ratio & Short Volume $1.38 -0.04 (-2.82%) (As of 11/1/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Chemomab Therapeutics Short Interest DataChemomab Therapeutics (CMMB) has a short interest of 93,600 shares, representing 0.74% of the float (the number of shares available for trading by the public). This marks a 29.10% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.3, indicating that it would take 0.3 days of the average trading volume of 189,181 shares to cover all short positions.Current Short Interest93,600 sharesPrevious Short Interest72,500 sharesChange Vs. Previous Month+29.10%Dollar Volume Sold Short$122,616.00Short Interest Ratio0.3 Days to CoverLast Record DateOctober 15, 2024Outstanding Shares14,360,000 sharesFloat Size12,620,000 sharesShort Percent of Float0.74%Today's Trading Volume36,597 sharesAverage Trading Volume189,181 sharesToday's Volume Vs. Average19% Short Selling Chemomab Therapeutics? Sign up to receive the latest short interest report for Chemomab Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCMMB Short Interest Over TimeCMMB Days to Cover Over TimeCMMB Percentage of Float Shorted Over Time Ad InvestorPlaceWhy Buffett, Bezos, & Congress Are Piling Into This One SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…Click here for the details Chemomab Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/15/202493,600 shares $122,616.00 +29.1%0.7%0.3 $1.31 9/30/202472,500 shares $113,825.00 +23.7%0.6%0.3 $1.57 9/15/202458,600 shares $104,601.00 -72.8%0.5%0.2 $1.79 8/31/2024215,200 shares $434,704.00 +1,003.6%1.8%1 $2.02 8/15/202419,500 shares $21,060.00 -75.0%0.2%0.1 $1.08 7/31/202478,000 shares $91,260.00 -25.7%0.7%0.6 $1.17 Get the Latest News and Ratings for CMMB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/15/2024105,000 shares $114,450.00 +4.5%0.9%1 $1.09 6/30/2024100,500 shares $91,706.15 +0.8%0.8%1 $0.91 6/15/202499,700 shares $112,661.00 +62.1%0.8%1 $1.13 5/31/202461,500 shares $65,805.00 -41.0%0.5%0.6 $1.07 5/15/2024104,200 shares $90,862.40 -10.7%0.9%1.1 $0.87 4/30/2024116,700 shares $81,690.00 -25.1%1.0%0.5 $0.70 4/15/2024155,800 shares $113,734.00 -29.8%1.3%0.7 $0.73 3/31/2024221,900 shares $172,860.10 +14.3%1.9%1 $0.78 3/15/2024194,200 shares $155,224.06 -20.5%1.8%0.8 $0.80 2/29/2024244,300 shares $167,345.50 +549.7%2.5%0.9 $0.69 2/15/202437,600 shares $22,936.00 +15.7%0.4%0.1 $0.61 1/31/202432,500 shares $18,752.50 +5.5%0.3%0 $0.58 1/15/202430,800 shares $17,217.20 -23.8%0.3%0 $0.56 12/31/202340,400 shares $20,604.00 +125.7%0.3%0 $0.51 12/15/202317,900 shares $9,039.50 -84.8%0.1%0 $0.51 11/30/2023117,900 shares $63,548.10 +287.8%1.2%0.1 $0.54 11/15/202330,400 shares $24,836.80 -5.6%0.3%0 $0.82 10/31/202332,200 shares $23,583.28 -28.1%0.3%1.7 $0.73 10/15/202344,800 shares $39,827.20 -2.6%0.5%2.4 $0.89 9/30/202346,000 shares $41,170.00 +23.0%0.5%2 $0.90 9/15/202337,400 shares $40,766.00 -9.2%0.4%0.7 $1.09 8/31/202341,200 shares $45,732.00 -8.9%0.4%0.2 $1.11 8/15/202345,200 shares $50,624.00 -19.6%0.5%0.3 $1.12 7/31/202356,200 shares $71,936.00 -43.4%0.5%0.3 $1.28 7/15/202399,200 shares $139,872.00 +6.6%0.9%0.6 $1.41 6/30/202393,100 shares $121,961.00 -69.1%1.1%0.5 $1.31 6/15/2023301,700 shares $512,890.00 -7.6%3.4%1.8 $1.70 5/31/2023326,500 shares $512,605.00 -22.8%3.7%11.9 $1.57 5/15/2023422,900 shares $689,327.00 -7.3%4.8%5.7 $1.63 4/30/2023456,300 shares $679,887.00 -11.8%4.9%1 $1.49 4/15/2023517,400 shares $838,188.00 +1.5%5.6%1.1 $1.62 3/31/2023510,000 shares $810,900.00 -15.7%5.5%1.1 $1.59 3/15/2023605,200 shares $913,852.00 -8.2%7.1%0.7 $1.51 2/28/2023658,900 shares $1.02 million +457.9%7.7%0.8 $1.55True paradigm shift (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. 2/15/2023118,100 shares $237,381.00 +3.9%1.4%0.1 $2.01 1/31/2023113,700 shares $261,510.00 -24.8%1.4%0.3 $2.30 1/15/2023151,200 shares $341,712.00 +269.7%1.8%0.3 $2.26 12/30/202240,900 shares $130,880.00 -19.7%0.5%0.1 $3.20 12/15/202250,900 shares $109,435.00 +155.8%0.6%1 $2.15 11/30/202219,900 shares $41,790.00 -69.9%0.3%0.5 $2.10 11/15/202266,100 shares $134,844.00 +66,000.0%0.8%1.6 $2.04 10/31/2022100 shares $204.00 No ChangeN/A0 $2.04 10/15/2022100 shares $200.00 -93.3%N/A0 $2.00 9/30/20221,500 shares $3,735.00 -83.0%0.0%0 $2.49 9/15/20228,800 shares $28,776.00 -36.7%0.1%0.2 $3.27 8/31/202213,900 shares $45,592.00 -42.3%0.2%0.3 $3.28 8/15/202224,100 shares $94,954.00 +230.1%0.3%0.5 $3.94 7/31/20227,300 shares $22,265.00 +49.0%0.1%0.2 $3.05 7/15/20224,900 shares $15,484.00 -78.0%0.1%0.1 $3.16 6/30/202222,300 shares $82,510.00 +147.8%0.3%0.6 $3.70 6/15/20229,000 shares $31,230.00 -14.3%0.1%0.2 $3.47 5/31/202210,500 shares $32,340.00 +34.6%0.1%0.2 $3.08 5/15/20227,800 shares $21,372.00 -34.5%0.1%0.1 $2.74 4/30/202211,900 shares $37,485.00 +205.1%0.2%0.2 $3.15 4/15/20223,900 shares $14,859.00 -76.8%0.1%0.1 $3.81 3/31/202216,800 shares $80,640.00 -32.5%0.2%0.2 $4.80 3/15/202224,900 shares $98,853.00 -26.1%N/A0.2 $3.97 2/28/202233,700 shares $146,258.00 +6.3%0.4%0.3 $4.34 2/15/202231,700 shares $137,578.00 +40.3%0.4%0.3 $4.34 1/31/202222,600 shares $110,740.00 -31.3%0.3%0.2 $4.90 1/15/202232,900 shares $216,482.00 +22.3%0.4%0.2 $6.58 12/31/202126,900 shares $185,610.00 -12.7%0.3%0.1 $6.90 12/15/202130,800 shares $224,224.00 -1.3%0.4%0.2 $7.28 11/30/202131,200 shares $288,600.00 -37.2%0.4%0.2 $9.25 11/15/202149,700 shares $506,940.00 -21.2%0.6%0.3 $10.20 10/29/202163,100 shares $633,984.63 +444.0%0.7%0.4 $10.05 10/15/202111,600 shares $105,444.00 -42.3%0.1%0.1 $9.09 9/30/202120,100 shares $222,708.00 -52.4%0.2%0.2 $11.08 9/15/202142,200 shares $531,720.00 -48.9%0.5%0.3 $12.60 8/31/202182,600 shares $1.21 million +140.1%1.0%0.3 $14.67 8/13/202134,400 shares $510,496.00 No Change0.4%0.1 $14.84 CMMB Short Interest - Frequently Asked Questions What is Chemomab Therapeutics' current short interest? Short interest is the volume of Chemomab Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 15th, traders have sold 93,600 shares of CMMB short. 0.74% of Chemomab Therapeutics' shares are currently sold short. Learn More on Chemomab Therapeutics' current short interest. What is a good short interest percentage for Chemomab Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.74% of Chemomab Therapeutics' floating shares are currently sold short. Is Chemomab Therapeutics' short interest increasing or decreasing? Chemomab Therapeutics saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 93,600 shares, an increase of 29.1% from the previous total of 72,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Chemomab Therapeutics' float size? Chemomab Therapeutics currently has issued a total of 14,360,000 shares. Some of Chemomab Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Chemomab Therapeutics currently has a public float of 12,620,000 shares. How does Chemomab Therapeutics' short interest compare to its competitors? 0.74% of Chemomab Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Chemomab Therapeutics: Mural Oncology plc (2.50%), Cidara Therapeutics, Inc. (1.09%), Reneo Pharmaceuticals, Inc. (15.65%), Kronos Bio, Inc. (1.71%), Precision BioSciences, Inc. (5.77%), Immuneering Co. (7.24%), Barinthus Biotherapeutics plc (0.01%), Monopar Therapeutics Inc. (2.84%), Theratechnologies Inc. (0.18%), Actinium Pharmaceuticals, Inc. (7.22%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.14 billion), AppLovin Co. ($3.15 billion), Paychex, Inc. ($2.69 billion), Nu Holdings Ltd. ($2.48 billion), Cencora, Inc. ($2.24 billion), International Paper ($2.04 billion), Tractor Supply ($1.96 billion), Coinbase Global, Inc. ($1.93 billion), Moderna, Inc. ($1.91 billion), and SoFi Technologies, Inc. ($1.84 billion). View all of the most shorted stocks. What does it mean to sell short Chemomab Therapeutics stock? Short selling CMMB is an investing strategy that aims to generate trading profit from Chemomab Therapeutics as its price is falling. CMMB shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Chemomab Therapeutics? A short squeeze for Chemomab Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CMMB, which in turn drives the price of the stock up even further. How often is Chemomab Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CMMB, twice per month. The most recent reporting period available is October, 15 2024. More Short Interest Resources from MarketBeat Related Companies Mural Oncology Short Interest Data Cidara Therapeutics Short Interest Data Reneo Pharmaceuticals Short Interest Data Kronos Bio Short Interest Data Precision BioSciences Short Interest Data Immuneering Short Interest Data Barinthus Biotherapeutics Short Interest Data Monopar Therapeutics Short Interest Data Theratechnologies Short Interest Data Actinium Pharmaceuticals Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CMMB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
